Santol drops eye

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

naphazoline (naphazoline hydrochloride)

Available from:

Liqvor CJSC

ATC code:

S01GA01

INN (International Name):

naphazoline (naphazoline hydrochloride)

Dosage:

0,3mg/ml

Pharmaceutical form:

drops eye

Units in package:

10ml plastic vial-dropper

Prescription type:

OTC

Authorization status:

Registered

Authorization date:

2016-02-04

Summary of Product characteristics

CYMMAPHA'I
XAPAITTEPI4CTI,IKA
TEKAPCTBE,HHOI'O
IPENAPATA
(sPC)
CAHTOJITM
Kan"rru
frra3r{bre
0,3
Mr/Nrr
(0,03%)
1, ItorvrruepqecKoe
r-IaHMeHoBaHr.te
npe[apaTa
:
CAHTOITM
(SANTOLTIUI)
2,
Ko.nuqecrBeHubrfi
u rcaqecrBeHsslfi
cocraB.
HaSa:orr
r4r{
a fHApoxnopur
Fop"u,
KucJrora
Harpun
rerpa6opar
.
10
HzO
frnuepnH
fiuHarpu.{
3Aerar
BeHgaJn(o
r-r
H.{
xnopuA
Bo.ua
Anfl
usrexuptfi
3.
OapruaueBTr{qecrcas
Sopnaa:
Kailrrn
4,
K.nunuqecKne
xa
pa
r{TeprrcruKI{
4.1
floxa3annfl
r( rpnMeHelrnro
O6rerqeHue
rryBcrBa
.qucxoira$opra
14
noKpacHenur
rna3 npr4:
-
o6ocrpenalt
ce3oHHoro
r.I
Kpyf
noroAllrlHoro
aJrJrepf
riqec
Koro Ko
H6roHKTxBr4Ta;
-
pa3,4pa)KeHHI4
KOHt,IOHKTT,IBbT
npx
npr4MeHeHI{I4
KOHTaKTHLIX
JII,IH3;
-pa3.rlpaxeulrr4
KoHr,IoHKTrrBbr
noA
BJllrHr4eM
BHerlrHlrx
Sarropoe
(n
r.q.
coJlHeqHofo
cBeTa, cHrapeTHoro
AbrMa,
nbIJIfi,
nbiJlbrlbl,
BoALI B
nJtaBaTeJibHoM
6accefiHe
r.r
4p.).
4,2,
LnOCO0
npuveHel|Hq
n
Ao3br
/)
. "
Bspocruu
r4
AerrM
craprue
6
rer
narnarutffil*
I-2
ranlu
.
s
Hr.rxrrr4fi
KorlbloHKrHBaJrbnbrfi
MeiuoK,
qepe3
KaxAbre
3-ff
tldd*.,
no
MexcAyHapoAnoe
HaHMeuoBalrHe
aKTHBHbrx
BerrlecrB:
Harla3oJrr{H
(naphazoline)
0,3
r
1 5 , 0
r
0,4
r
5 O r
e
)
v
,
0 5 r
v
)
"
0 , 1
f
I o l
n
fJra3Hbre
0,3
ur/ul
(0,03%)
fnurelbHocrb
npnMener{r4fl
-
5-7
A}refr
Heo6xonHMocrb
6olee
ArruTerrbr{oro
rrer{eHaff
rII"lAHBllAyanbHO
B
Kalr(lloM
KoHKpeTHOM
Crryqae.
geo6xp,uHMocrH.
0npeAeJrfleTcfl
Bpar{oM
4.3.
ilporneonoKa3aHurl
3axprnoyronrHar
r.,'rayKoMa,
agaroMarrecxlr
yexuft
yror
neperueft
xauepu
uasa,
NOBbIIIICI{HA'I
I{YBCTBI4TEJIbHOCTL
K KOMIIOHCHTAM
NPENAPATA.
4.4.
Oco6sle
yKa3aHliq
Ecllr
na
$one
aeueuua
ua6lrcgato.rcq
croftxrle
er4MnroMbr
MecrHoro
pa3ApaxeHlu
r'iJrr{
pa3BHTr're
cficreM'r,lx
peaxuuir,
npenapar
cJreAyer
orMeHHTb.
He
cre4ye.r
npl4MeHrr6
npenapar
60nee
7
4Uefi
Anu
c
r.HrepBaJroM
MeHee
3
.{,
r.K. cyuecrByer
pacK
pa3'rrrur
gOSeKTa
orpaxe*ar,
np'r
KoropoM
Ha6nrc4aercx
BTopraq'oe
ycareHr4e
oreKa
14
yBenatleHrze
3(ccy,qaul{r4,
a
raKx(e
Bo3MoXH6r
C,rOtixue
H3MeHeHH'
3NI4TCJI14,I,
He
c'lregyer
npvMeHrrb
npeflapar
npi.
3arrx'oM
TeqeHr